Ad is loading...
NGNE
Price
$20.60
Change
+$5.01 (+32.14%)
Updated
Nov 22, 03:31 PM (EDT)
SNDX
Price
$16.11
Change
+$0.51 (+3.27%)
Updated
Nov 22, 03:37 PM (EDT)
103 days until earnings call
Ad is loading...

NGNE vs SNDX

Header iconNGNE vs SNDX Comparison
Open Charts NGNE vs SNDXBanner chart's image
Neurogene
Price$20.60
Change+$5.01 (+32.14%)
Volume$3.64K
CapitalizationN/A
Syndax Pharmaceuticals
Price$16.11
Change+$0.51 (+3.27%)
Volume$8.76K
CapitalizationN/A
NGNE vs SNDX Comparison Chart
Loading...
NGNE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NGNE vs. SNDX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a Hold and SNDX is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (NGNE: $15.59 vs. SNDX: $15.60)
Brand notoriety: NGNE and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGNE: 124% vs. SNDX: 314%
Market capitalization -- NGNE: $231.59M vs. SNDX: $1.36B
NGNE [@Biotechnology] is valued at $231.59M. SNDX’s [@Biotechnology] market capitalization is $1.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGNE’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • NGNE’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than NGNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGNE’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • NGNE’s TA Score: 4 bullish, 6 bearish.
  • SNDX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than NGNE.

Price Growth

NGNE (@Biotechnology) experienced а -60.23% price change this week, while SNDX (@Biotechnology) price change was -7.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

NGNE is expected to report earnings on Nov 14, 2023.

SNDX is expected to report earnings on Mar 05, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.36B) has a higher market cap than NGNE($232M). NGNE YTD gains are higher at: -19.556 vs. SNDX (-27.811). NGNE has higher annual earnings (EBITDA): -49.96M vs. SNDX (-296.86M). SNDX has more cash in the bank: 406M vs. NGNE (66.6M). SNDX has less debt than NGNE: SNDX (854K) vs NGNE (14.5M). SNDX has higher revenues than NGNE: SNDX (16M) vs NGNE (925K).
NGNESNDXNGNE / SNDX
Capitalization232M1.36B17%
EBITDA-49.96M-296.86M17%
Gain YTD-19.556-27.81170%
P/E RatioN/AN/A-
Revenue925K16M6%
Total Cash66.6M406M16%
Total Debt14.5M854K1,698%
FUNDAMENTALS RATINGS
NGNE vs SNDX: Fundamental Ratings
NGNE
SNDX
OUTLOOK RATING
1..100
559
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
9156
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6664
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
9595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGNE's Valuation (61) in the null industry is in the same range as SNDX (85) in the Biotechnology industry. This means that NGNE’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (56) in the Biotechnology industry is somewhat better than the same rating for NGNE (91) in the null industry. This means that SNDX’s stock grew somewhat faster than NGNE’s over the last 12 months.

NGNE's SMR Rating (97) in the null industry is in the same range as SNDX (98) in the Biotechnology industry. This means that NGNE’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Price Growth Rating (64) in the Biotechnology industry is in the same range as NGNE (66) in the null industry. This means that SNDX’s stock grew similarly to NGNE’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for NGNE (100) in the null industry. This means that SNDX’s stock grew significantly faster than NGNE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGNESNDX
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 19 days ago
85%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 11 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
NGNE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SSDZX36.100.48
+1.35%
DWS Small Cap Growth R6
FSUVX22.680.15
+0.67%
Fidelity SAI US LowVolatility Idx
ATWCX22.720.11
+0.49%
AB Tax-Managed Wealth Apprec Strat C
VGWLX26.830.10
+0.37%
Vanguard Global Wellington Investor
GFVSX17.32N/A
N/A
Goldman Sachs Focused Value Instl

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
+1.70%
BRNS - NGNE
51%
Loosely correlated
+9.93%
RNAZ - NGNE
48%
Loosely correlated
+13.03%
SNDX - NGNE
40%
Loosely correlated
-2.19%
BPTSY - NGNE
38%
Loosely correlated
N/A
ZNTL - NGNE
37%
Loosely correlated
+1.60%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with ABOS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-2.19%
ABOS - SNDX
48%
Loosely correlated
-2.53%
RAPT - SNDX
45%
Loosely correlated
-1.87%
BEAM - SNDX
45%
Loosely correlated
-3.72%
VCYT - SNDX
45%
Loosely correlated
-0.66%
ALEC - SNDX
43%
Loosely correlated
+3.44%
More